Saturday June 4th: Poster Presentation
Abstract #8025
"Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM)."
Michael Wang, MD
Saturday June 4th: Poster Presentation
Abstract #8026
"The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naïve relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study"
A. K. Stewart, MBChB
Saturday June 4th: Poster Presentation
Abstract #8027
"PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis."
David S. Siegel, MD, PhD
Saturday June 4th: Poster Presentation
Abstract #8028
"Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM)."
Jackie Szymonifka
Monday June 6th: Poster Presentation
Abstract #6623
"Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL."
Joseph M. Flynn, DO
Monday June 6th: Poster Presentation
Abstract #TPS225
"A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM)."
Philippe Moreau, MD
Monday June 6th: Poster Presentation
Abstract #6632
"Effects of eltrombopag on human cord blood hematopoietic stem cell/primitive progenitor cell expansion."
Hongliang Sun, PhD
Monday June 6th: Poster Presentation
Abstract #6571
"Interim PK analysis results of a phase IIa, open-label, randomized, pharmacokinetic comparative, cross-over study of melphalan HCl for injection (propylene glycol-free) and alkeran for injection for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation."
Omar S. Aljitawi, MD
Monday June 6th: Poster Presentation
Abstract #3080
"A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results."
Monica M. Mita, MD